- December 03-04, 2019
09:00 AM - 01:00 PM EST
Meeting and event space.
Answers to commonly asked questions including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed on FDA.gov or Heifer.org.
1 World Ave
Little Rock, AR 72202
NCTR’s Science Advisory Board (SAB) meeting will be held at the Heifer Center in Little Rock on December 3-4, 2019, ending at approximately noon on December 4th. This is a public meeting.
On December 3, 2019, the SAB Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The SAB will be presented with an overview of the SAB Subcommittee Site Visit Report and a response to this review. There will be a statement given by the FDA Chief Scientist. The Center for Biologics and Evaluation and Research, Center for Drug Evaluation and Research, Center for Devices and Radiological Health, Center for Food Safety and Applied Nutrition, Center for Tobacco Products, Center for Veterinary Medicine and the Office of Regulatory Affairs will each briefly discuss their center-specific research strategic needs and potential areas of collaboration. There will be a public comment period in-between these Center presentations. There will be updates from the NCTR Research Divisions on December 3-4, 2019. On December 4, there will be open discussion of all the information presented and then the open session of the meeting will close so the SAB members can discuss personnel issues at NCTR.
FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at Advisory Committees. Scroll down to the appropriate advisory committee meeting link.
On December 3, 2019, from 8 a.m. to 5:55 p.m. (CST), and December 4, 2019, from 8:00 a.m. to 11:30 a.m. (CST), the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before November 18, 2019. Oral presentations from the public will be scheduled between approximately 1:00 p.m. and 2:00 p.m. (CST). Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 18, 2019. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 20, 2019.
Closed Committee Deliberations
On December 4, 2019, from 11:30 a.m. to 12:00 p.m. (CST), the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to permit discussion of information concerning individuals associated with the research programs at NCTR.
- Donna L. Mendrick, Ph.D., Designated Federal Officer
- National Center for Toxicological Research
10903 New Hampshire Avenue
Building 32, Room 2208
Silver Spring, MD 209903-0002
FDA Advisory Committee Information Line
(301-443-0572 in the Washington DC area)
Please call the Information Line for up-to-date information on this meeting.
A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Web site and call the FDA Advisory Committee Information Line to learn about possible modifications before coming to the meeting.
Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Lauren Tesh at (301) 796-9001 at least 7 days in advance of the meeting.
Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.
FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).